Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Italian Stock Exchange  >  Molecular Medicine SpA    MLM   IT0001080248

MOLECULAR MEDICINE SPA

(MLM)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Data on Molecular Medicine Detailed by Researchers at University of Catania (Anti-angiogenic effect of quercetin and its 8-methyl pentamethyl ether derivative in human microvascular endothelial cells): Biotechnology - Molecular Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 05:27pm EDT

2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- A new study on Biotechnology - Molecular Medicine is now available. According to news reporting originating in Catania, Italy, by NewsRx journalists, research stated, “Angiogenesis is involved in many pathological states such as progression of tumours, retinopathy of prematurity and diabetic retinopathy. The latter is a more complex diabetic complication in which neurodegeneration plays a significant role and a leading cause of blindness.”

Financial supporters for this research include Ministero dell’Istruzione, dell’Universita e della Ricerca, Universita di Catania.

The news reporters obtained a quote from the research from the University of Catania, “The vascular endothelial growth factor (VEGF) is a powerful pro-angiogenic factor that acts through three tyrosine kinase receptors (VEGFR-1, VEGFR-2 and VEGFR-3). In this work we studied the anti-angiogenic effect of quercetin (Q) and some of its derivates in human microvascular endothelial cells, as a blood retinal barrier model, after stimulation with VEGF-A. We found that a permethylated form of Q, namely 8MQPM, more than the simple Q, is a potent inhibitor of angiogenesis both in vitro and ex vivo. Our results showed that these compounds inhibited cell viability and migration and disrupted the formation of microvessels in rabbit aortic ring. The addition of Q and more significantly 8MQPM caused recoveries or completely re-establish the transendothelial electrical resistance (TEER) to the control values and suppressed the activation of VEGFR2 downstream signalling molecules such as AKT, extracellular signal-regulated kinase, and c-Jun N-terminal kinase.”

According to the news reporters, the research concluded: “Taken together, these data suggest that 8MQPM might have an important role in the contrast of angiogenesis-related diseases.”

For more information on this research see: Anti-angiogenic effect of quercetin and its 8-methyl pentamethyl ether derivative in human microvascular endothelial cells. Journal of Cellular and Molecular Medicine, 2019;():. Journal of Cellular and Molecular Medicine can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA. (Wiley-Blackwell - http://www.wiley.com/; Journal of Cellular and Molecular Medicine - http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1582-4934)

Our news correspondents report that additional information may be obtained by contacting G. Lupo, Section of Medical Biochemistry, Dept. of Biomedical and Biotechnological Sciences (Biometec), School of Medicine, University of Catania, Catania, Italy. Additional authors for this research include M.T. Cambria, M. Olivieri, C. Rocco, N. Caporarello, A. Longo, G. Zanghi, M. Salmeri, M.C. Foti and C.D Anfuso.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1111/jcmm.14455. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher of the Journal of Cellular and Molecular Medicine can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Copyright © 2019 NewsRx LLC, Disease Prevention Daily, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MOLECULAR MEDICINE SPA
06/27MOLECULAR MEDICINE : MolMed announces the decision to suspend the enrollment of ..
PU
06/05MOLECULAR MEDICINE : KU awards 51 M.Phil and 21 PhD degrees in various disciplin..
AQ
06/04MOLECULAR MEDICINE : KU awards 51 MPhil, 21 PhD degrees in various disciplines
AQ
05/02MOLECULAR MEDICINE : MolMed at the 22nd ASGCT congress on continuous innovation ..
PU
04/30MOLECULAR MEDICINE : Shareholders meeting approved the Financial Statement 2018...
PU
04/25MOLECULAR MEDICINE : MolMed at the “Cell & Gene Meeting on the Med” ..
PU
04/09MOLECULAR MEDICINE : Notice of publication of the Annual Report 2018 and other d..
PU
04/05MOLECULAR MEDICINE : KU awards 51 PhD, 24 MPhil degrees in various disciplines
AQ
04/05MOLECULAR MEDICINE : KU awards 51 PhD, 24 MPhil degrees in various disciplines
AQ
04/04MOLECULAR MEDICINE : Karachi University awards 51 PhD and 24 MPhil degrees in va..
AQ
More news
Financials (EUR)
Sales 2017 -
EBIT 2017 -
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 -
Capi. / Sales2017 -
Capi. / Sales2018 -
Capitalization 169 M
Chart MOLECULAR MEDICINE SPA
Duration : Period :
Molecular Medicine SpA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOLECULAR MEDICINE SPA
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 0,36  €
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Riccardo Palmisano Chief Executive Officer & Director
Carlo Incerti Chairman
Simona Rovetta Operations Director
Salvatore Calabrese Chief Financial Officer & Director-Administration
Antonio Lambiase Director-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
MOLECULAR MEDICINE SPA31.54%187
IQVIA HOLDINGS INC34.91%30 701
LONZA GROUP36.75%26 363
INCYTE CORPORATION32.91%18 177
CELLTRION, INC.--.--%16 143
EXACT SCIENCES CORPORATION89.89%15 300